Chemed Corporation is a holding company that operates two wholly owned subsidiaries engaged in distinct service industries. The VITAS segment, operated through VITAS Healthcare Corporation, provides hospice and palliative care services to patients, primarily in their homes and in inpatient units within hospitals and nursing facilities. VITAS serves a patient base that is predominantly Medicare recipients and operates programs across multiple U.S. states, with a significant presence in Florida. The Roto-Rooter segment, operated through Roto-Rooter Corporation, provides plumbing repair, drain cleaning, excavation, and water restoration services to residential, commercial, and municipal customers. Roto-Rooter utilizes a mixed operating model consisting of company-owned branches, independent contractors, and franchisees to serve the United States and Canada. Chemed was incorporated in 1970 as a subsidiary of W.R. Grace & Co., succeeding to its Special Products Group business in 1971, and remained a subsidiary until 1982. The company manages its operating units on a decentralized basis, with corporate management responsible for strategic planning, capital allocation, and executive selection.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Conglomerates Homepage chemed.com
Sector Industrials IR page ir.chemed.com
Tags
hospice care, palliative care, plumbing services, drain cleaning, water restoration, excavation, franchise operations, home health, end-of-life care, residential services, commercial services, VITAS Healthcare Corporation, Roto-Rooter Corporation, VITAS, Roto-Rooter, Innovative Hospice Care
Press page —

Metrics

Valuation  
Market cap $ 7.127B
Market cap (USD) $ 7.127B
P/E 26.24
PEG 12.84
P/BV 8.27
P/S 2.68
P/OCF 19.63
P/FCF 24.12
Dividend yield <0.01%
Turnover / mcap —
Returns  
ROE 25.3%
ROI 26.3%
ROIC 25.0%
Profit margin 10.5%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 2.0%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 27.4%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 26
Quality score 0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 2.53B 1.531B 1.315B 1.202B 1.261B 1.335B 1.281B 1.198B 1.667B 1.577B 1.543B 1.456B 1.413B 1.43B 1.356B 1.281B 1.19B 1.149B 1.1B 1.019B 926.477M 735.341M 308.871M 314.176M 477.116M 500.685M
Net profit 265.238M 301.999M 272.509M 249.624M 268.55M 319.466M 219.923M 205.544M 98.177M 108.743M 110.274M 99.317M 77.227M 89.304M 85.979M 81.831M 73.784M 71.017M 63.976M 50.651M 35.817M 27.512M -3.435M -1.813M -10.375M 20.584M
Free cash flow 325.477M 367.966M 273.445M 252.561M 249.922M 430.458M 248.227M 234.266M 98.195M 95.621M 127.365M 66.708M 121.523M 96.516M 144.751M 60.373M 139.336M 85.989M 72.944M 76.602M 54.057M 75.865M 11.412M 17.668M 19.06M 32.339M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 427.86 529.8 584.75 510.43 529.04 532.61 439.26 283.28 243.02 160.41 149.8 105.67 76.62 68.59 51.23 63.49 48.09 39.77 55.84 37.06 — — — — — —
Price performance 12m -0.19 -0.09 0.15 -0.04 -0.01 0.21 0.55 0.17 0.52 0.07 0.42 0.38 0.12 0.34 -0.19 0.32 0.21 -0.29 0.51 — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 132M 114M 120M 144M 127M 137M 139M 182M 171M 183M
↳ YoY growth +24.2% -13.9% +5.1% +20.4% -11.8% +8.2% +1.6% +30.2% -5.7% +6.7%
↳ 5y CAGR +11.1% +4.0% +5.4% +2.9% +3.6% +0.8% +4.2% +8.7% +3.5% +7.6%
Borrowings, current (USD) 8.75M 10M — — — — 5M — — —
Borrowings, non-current (USD) 100M 91.2M 89.2M 90M — 185M 92.5M — — —
Lease liabilities (USD) — — — 126M 135M 139M 150M 139M 141M 144M
Cash and deposits (USD) 15.3M 11.1M 4.83M 6.16M 163M 32.9M 74.1M 264M 178M 74.5M
Intangible assets (USD) 55.1M 54.9M 68.3M 126M 118M 108M 99.7M 90.3M 92.2M 82.8M
Right-of-use assets (USD) — — — 112M 123M 125M 136M 126M 127M 131M
Net debt (borrowings + leases - cash) (USD) 93.4M 90.1M 84.4M 210M — 291M 173M — — —
Cash flow detail
Operating cash flow (USD) 135M 162M 287M 301M 489M 309M 310M 330M 417M 388M
Purchases of property, plant and equipment (USD) -39.8M -64.3M -52.9M -53M -58.8M -58.7M -57.3M -56.9M -49.5M -62.8M
Change in receivables (cash effect) (USD) -42.1M 1.07M -5.57M -19.2M 12.8M -8.43M -2.41M -41.5M 10.7M -11.6M
Change in inventories (cash effect) (USD) 559,000 421,000 -351,000 -1.76M 367,000 -3.01M -162,000 -1.73M 3.83M 650,000
Change in payables (cash effect) (USD) 891,000 12.9M 8.94M 28.4M 19.1M 9.83M 15.3M -9.35M -9.28M -5.19M
Dividends paid (cash effect) (USD) -16.4M -17.4M -18.7M -19.8M -21.1M -22M -22M -23.5M -27.1M -31.7M
Share buybacks (cash effect) (USD) -102M -94.6M -159M -92.6M -176M -576M -115M -67.7M -361M -432M
Interest paid (cash effect) (USD) -3.05M -3.63M -4.18M -4.13M -2.03M -1.4M -3.7M -2.65M -1.16M -1.35M
Income taxes paid (cash effect) (USD) -60.9M -42.3M -9.75M -44.1M -61.5M -99.4M -65.9M -73.9M -98.7M -103M
Share-based compensation (USD) 13.8M 16.3M 19.2M 21.3M 26.8M 31.4M 33.6M 40.8M 52.1M 38.7M
Operating cash flow before change in receivables (USD) 178M 161M 293M 320M 477M 317M 312M 372M 407M 400M
Free cash flow (OCF - PPE - intangibles) (USD) 95.6M 98.2M 234M 248M 430M 250M 253M 273M 368M 325M
Income detail
Provision for credit losses (USD) 16.3M 17.3M — — — — — — — —
Credit cost ratio (credit losses / average receivables) (%) 13.7% 14.1% — — — — — — — —
Reported Feb 27, 2017 Feb 26, 2018 Feb 27, 2019 Feb 26, 2020 Feb 26, 2021 Feb 28, 2022 Feb 27, 2023 Feb 29, 2024 Feb 28, 2025 Feb 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Chemed Corporation Declares Quarterly Dividend of 70 Cents Bull 0 Bear 0 Capital return

November 6, 2026 at 11:23 AM EST

Download PDF

CINCINNATI, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 70-cents per share on the Company’s capital stock, payable on December 4, 2026, to shareholders of record as of November 16, 2026. This is equal to the dividend paid in September 2026. This represents the 222nd consecutive quarterly dividend paid by Chemed in its 55 years as a public company.

Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation (www.chemed.com) operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care and Roto-Rooter is the nation’s leading provider of plumbing and drain cleaning services.

Statements in this press release or in other Chemed communications may relate to future events or Chemed's future performance. Such statements are forward-looking statements and are based on present information Chemed has related to its existing business circumstances. Investors are cautioned that such forward-looking statements are subject to inherent risk that actual results may differ materially from such forward-looking statements. Further, investors are cautioned that Chemed does not assume any obligation to update forward-looking statements based on unanticipated events or changed expectations.

| CONTACT: | Michael D. Witzeman |

| | (513) 762-6714 |

Primary Logo

Source: Chemed Corp.

Close

LEGAL TERMS AND PRIVACY

By clicking “Accept,” you have read and agree to the Terms of Use and to the collection and use of your information by cookies and similar technologies, as set forth in our Privacy Policy.

Accept

November 2, 2026 at 9:00 AM EST

Download PDF

CINCINNATI, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE) today announced that it will deliver a presentation at the UBS 2026 Global Healthcare Conference on Monday, November 9, 2026, at approximately 8:45 a.m. (ET) at the PGA National Resort in Palm Beach Gardens, Florida.

The presentation will be webcast live and can be accessed, along with the presentation materials, through the Chemed website at www.chemed.com (Investor Relations). The webcast replay will be available within 24 hours of the live presentation and will be accessible for 90 days.

Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation (www.chemed.com) operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care and Roto-Rooter is the nation’s leading provider of plumbing and drain cleaning services.

Statements in this press release or in other Chemed communications may relate to future events or Chemed's future performance. Such statements are forward-looking statements and are based on present information Chemed has related to its existing business circumstances. Investors are cautioned that such forward-looking statements are subject to inherent risk and that actual results may differ materially from such forward-looking statements. Further, investors are cautioned that Chemed does not assume any obligation to update forward-looking statements based on unanticipated events or changed expectations.

| CONTACT: | Michael D. Witzeman |

| | (513) 762-6714 |

Primary Logo

Source: Chemed Corp.

Close

LEGAL TERMS AND PRIVACY

By clicking “Accept,” you have read and agree to the Terms of Use and to the collection and use of your information by cookies and similar technologies, as set forth in our Privacy Policy.

Accept

Chemed Reports Third-Quarter 2026 Results Bull 4 Bear 0 Results

October 27, 2026 at 4:15 PM EDT

CINCINNATI, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its third quarter ended September 30, 2026, versus the comparable prior-year period.

Results for Quarter Ended September 30, 2026

Consolidated operating results:

  • Revenue increased 10.6% to $690.9 million

  • GAAP Diluted Earnings-per-Share (EPS) of $5.45, an increase of 22.2%

  • Adjusted Diluted EPS of $6.75, an increase of 28.1%

VITAS segment operating results:

  • Net Patient Revenue of $457.4 million, an increase of 12.2%

  • Average Daily Census (ADC) of 24,428, an increase of 9.4%

  • Admissions of 18,995, an increase of 7.2%

  • Net Income, excluding certain discrete items, of $70.8 million, an increase of 44.7%

  • Adjusted EBITDA, excluding Medicare Cap, of $92.5 million, an increase of 31.4%

  • Adjusted EBITDA margin, excluding Medicare Cap, of 20.2%, an increase of 318-basis points

Roto-Rooter segment operating results:

  • Revenue of $233.5 million, an increase of 7.5%

  • Net Income, excluding certain discrete items, of $33.3 million, a decline of 1.8%

  • Adjusted EBITDA of $48.2 million, a decline of 2.5%

  • Adjusted EBITDA margin of 20.6%, a decline of 213-basis points

VITAS

VITAS net revenue was $457.4 million in the third quarter of 2026, which is an increase of 12.2% when compared to the prior-year period. This revenue increase is comprised primarily of a 9.4% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.2%. Acuity mix shift negatively impacted revenue growth 25-basis points in the quarter when compared to the prior-year period’s revenue and level-of-care mix. The combination of Medicare Cap and other contra revenue changes positively impacted revenue growth by 85-basis points.

Total VITAS admissions increased 7.2% in the third quarter of 2026 compared to the third quarter of 2025.

In the third quarter of 2026, VITAS accrued $828,000 in Medicare Cap billing limitation. This compares to the Medicare Cap billing limitation recorded in the third quarter of 2025 of $6.1 million. No Medicare Cap billing limitation was recorded in the third quarter of 2026 for the Florida combined program, and none is anticipated for the 2026 fiscal period.

Of VITAS’ 33 Medicare provider numbers, 21 provider numbers have an anticipated full-year Medicare Cap cushion of 10% or greater, seven provider numbers have a cushion between 0% and 10%, and five provider numbers have a Medicare Cap billing limitation totaling $6.1 million.

Average revenue per patient per day in the third quarter of 2026 was $209.11 which is 196-basis points above the prior-year period. Reimbursement for routine home care and high-acuity care averaged $187.69 and $1,147.26, respectively. During the quarter, high-acuity days-of-care were 2.2% of total days of care, a decline of 5-basis points when compared to the prior-year quarter.

The third quarter 2026 gross margin, excluding Medicare Cap, was 25.4%, a 221-basis point increase from the same period of 2025. Selling, general and administrative expenses were $23.1 million in the third quarter of 2026 compared to $25.2 million in the prior-year quarter.

Adjusted EBITDA, excluding Medicare Cap, totaled $92.5 million in the quarter, an increase of 31.4% when compared to the prior-year period. Adjusted EBITDA margin in the quarter, excluding Medicare Cap, was 20.2%.

Roto-Rooter

Roto-Rooter generated quarterly revenue of $233.5 million in the third quarter of 2026, an increase of 7.5%, when compared to the prior-year quarter.

Roto-Rooter branch commercial revenue in the quarter totaled $59.9 million, an increase of 9.0% from the prior-year period. This aggregate commercial revenue change consisted of plumbing increasing 10.6%, drain cleaning increasing 6.8%, excavation increasing 5.5% and water restoration increasing 30.7%.

Roto-Rooter branch residential revenue in the quarter totaled $158.8 million, an increase of 5.2% over the prior-year period. This aggregate residential revenue change consisted of excavation increasing 7.8%, plumbing increasing 5.9%, water restoration increasing 6.2% and drain cleaning increasing 4.5%.

In the third quarter of 2026, revenue from independent contractors was $16.9 million which is flat compared to the same period of 2025.

Roto-Rooter’s third quarter 2026 gross margin was 50.3%. This compares to the prior-year quarter’s gross margin of 50.7%. Roto-Rooter’s selling, general and administrative expenses were $71.0 million in the quarter, which is an increase of 17.1% compared to the third quarter of 2025.

Adjusted EBITDA in the third quarter of 2026 totaled $48.2 million, a decline of 2.5% when compared to the third quarter of 2025. Adjusted EBITDA margin in the quarter was 20.6% which represents a 213-basis point decline from the third quarter of 2025.

During the third quarter of 2026, Roto-Rooter re-acquired multiple franchise territories in California for approximately $62.5 million. Collectively, these territories include a population of over 12 million people. Slightly over half of the revenue associated with acquired territories will become part of our owned and operated branch locations. Two new branches will be established in Sacramento and San Diego while other territories will be absorbed by existing branches. The remaining locations will become part of our independent contractor operating model.

Chemed Consolidated

As of September 30, 2026, Chemed had total cash and cash equivalents of $48.4 million and $236.0 million in long-term debt.

In April 2026, Chemed entered into a new five-year $450 million Amended and Restated Credit Agreement (Credit Agreement). This Credit Agreement consists of a $450 million revolving line of credit and a $250 million expansion feature. The interest rate on this Credit Agreement has a floating rate that is currently SOFR plus 100-basis points. There is approximately $166.7 million undrawn borrowing capacity under the Credit Agreement after excluding $47.3 million for Letters of Credit.

During the quarter, the Company repurchased 125,000 shares of Chemed stock for $66.0 million which equates to a cost per share of $528.24. Over the trailing 12-months, the Company has repurchased 1,235,000 shares of Chemed stock at an average price of $427.62 per share. As of September 30, 2026, there was approximately $73.7 million of remaining share repurchase authorization under the Company’s plan.

Guidance Update

Based on the Company’s financial results through September 30, 2026, we estimate that we will be at or slightly above the high-end of our full-year 2026 adjusted EPS guidance issued in conjunction with our press release, dated July 28, 2026, discussing our second quarter 2026 earnings. Further operational detail will be provided during the investor conference call.

Conference Call

As previously disclosed, Chemed will host a conference call and webcast at 10 a.m. ET, on Wednesday October 28, 2026, to discuss the company's quarterly results and to provide an update on its business. Participants may access a live webcast of the conference call through the investor relations section of Chemed’s website, Investor Relations Home | Chemed Corporation or the hosting website https://edge.media-server.com/mmc/p/v5gcs68f.

Participants may also register via teleconference at: https://register-conf.media-server.com/register/BId8ccb8a390cc4b6fbb29ab2b99a55028.

Once registration is completed, participants will be provided with a dial-in number containing a personalized conference code to access the call. All participants are instructed to dial-in 15 minutes prior to the start time.

A taped replay of the conference call will be available beginning approximately two hours after the call's conclusion. You may access the replay via webcast through the investor relations section of Chemed’s website.

Chemed operates in the healthcare field through its VITAS Healthcare Corporation subsidiary. VITAS provides daily hospice services to patients with severe, life-limiting illnesses. This type of care is focused on making the terminally ill patient's final days as comfortable and pain-free as possible.

Chemed operates in the residential and commercial plumbing and drain cleaning industry under the brand name Roto-Rooter. Roto-Rooter provides plumbing, drain cleaning, and water cleanup services through company-owned branches, independent contractors and franchisees in the United States and Canada. Roto-Rooter also has licensed master franchisees in the republics of Indonesia and Singapore, and the Philippines.

This press release contains information about Chemed’s EBITDA, Adjusted EBITDA, and Adjusted Diluted EPS, which are not measures derived in accordance with GAAP and which exclude components that are important to understanding Chemed’s financial performance. In reporting its operating results, Chemed provides EBITDA, Adjusted EBITDA and Adjusted Diluted EPS measures to help investors and others evaluate the Company’s operating results, compare its operating performance with that of similar companies that have different capital structures and evaluate its ability to meet its future debt service, capital expenditures and working capital requirements. Chemed’s management similarly uses EBITDA, Adjusted EBITDA, and Adjusted Diluted EPS to assist it in evaluating the performance of the Company across fiscal periods and in assessing how its performance compares to its peer companies. These measures also help Chemed’s management to estimate the resources required to meet Chemed’s future financial obligations and expenditures. Chemed’s EBITDA, Adjusted EBITDA and Adjusted Diluted EPS should not be considered in isolation or as a substitute for comparable measures calculated and presented in accordance with GAAP. We calculated Adjusted EBITDA margin by dividing Adjusted EBITDA by service revenue and sales. A reconciliation of Chemed’s Net Income to its EBITDA, Adjusted EBITDA and Adjusted Diluted EPS is presented in the tables following the text of this press release.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 REGARDING FORWARD-LOOKING INFORMATION

Statements in this press release contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods and are based upon assumptions subject to certain known and unknown risks, uncertainties, contingencies and other factors, including, but not limited to, the impact of laws and regulations on Chemed’s operations, including Medicare Cap and Medicare reimbursement rates, Chemed’s estimates of the effect of Medicare Cap on VITAS’ revenues and future prospects, Chemed’s expectations regarding VITAS’ patient mix and Chemed’s expectations regarding demand for Roto-Rooter’s services.

Prompts

Chemed Corp (ticker CHE), listed in United States.

Company History

Date Change Detail
Jul 21, 2003 Renamed CHEMED CORP → ROTO-ROOTER INC

ETFs Holding Chemed Corp

ETF Weight in ETF Shares Market value As of
KONG 2.75% 1,284 $ 598.01K Jun 30, 2026
OSCV 2.18% 28,855 $ 15.358M Jul 31, 2026
KDVD 1.57% 285 $ 132.736K Jun 30, 2026
HSMV 1.03% 103 $ 56.593K Nov 16, 2026
ABFL 0.85% 8,399 $ 4.47M Jul 31, 2026
PAPI 0.62% 5,297 $ 2.467M Jun 30, 2026
SDVD 0.54% 8,959 $ 4.933M Nov 11, 2026
FLDZ 0.47% 41 $ 19.095K Jun 30, 2026
VFQY 0.43% 4,258 $ 2.209M Aug 31, 2026
SIXL 0.43% 1,641 $ 902.878K Nov 12, 2026
AFMC 0.43% 2,042 $ 1.122M Nov 16, 2026
JMEE 0.21% 10,879 $ 5.948M Nov 17, 2026
SAGP 0.21% 344 $ 160.215K Jun 30, 2026
SMDX 0.20% 465 $ 255.494K Nov 17, 2026
SELV 0.15% 809 $ 376.784K Jun 30, 2026
DFAS 0.15% 91,606 $ 50.402M Nov 12, 2026
VFMF 0.14% 2,704 $ 1.403M Aug 31, 2026
REMC 0.14% 10 $ 4,657.40 Jun 30, 2026
VFMV 0.12% 1,088 $ 564.356K Aug 31, 2026
SYZ 0.12% 176 $ 81.97K Jun 30, 2026
IEDI 0.09% 47 $ 25.016K Jul 31, 2026
BALI 0.08% 2,189 $ 1.203M Nov 16, 2026
SFGV 0.08% 1,604 $ 880K Nov 18, 2026
RILA 0.06% 46 $ 24.484K Jul 31, 2026
AVMC 0.05% 474 $ 260.439K Nov 16, 2026
DXUV 0.04% 4,277 $ 2.353M Nov 12, 2026
DFAC 0.03% 55,587 $ 30.584M Nov 12, 2026
IALT 0.03% 3,718 $ 2.043M Nov 16, 2026
MSSM 0.03% 392 $ 203.334K Aug 31, 2026
DCOR 0.02% 18,811 $ 10.35M Nov 12, 2026
AVSU 0.02% 142 $ 78.022K Nov 16, 2026
DFSU 0.01% 647 $ 355.979K Nov 12, 2026
DFAU 0.01% 3,320 $ 1.827M Nov 12, 2026
DFUS 0.01% 3,960 $ 2.179M Nov 12, 2026
AVUS 0.01% 3,367 $ 1.85M Nov 16, 2026
DFUV 0.01% 2,829 $ 1.557M Nov 12, 2026
VSLU 0.01% 116 $ 54.026K Jun 30, 2026
MSLC 0.01% 538 $ 279.066K Aug 31, 2026
EBI 0.00% 23 $ 11.93K Aug 31, 2026
AVLC 0.00% 71 $ 39.011K Nov 16, 2026
NTRL 0.00% 428 $ 0.00 Nov 16, 2026